Table 1.
Patient demographics and biochemical variables before and after evolocumab treatment
| Monogenic (He) hypercholesterolemia | Polygenic hypercholesterolemia | P value | |
|---|---|---|---|
| Number | 32 | 7 | - |
| Female N (%) | 12 (37.5%) | 2 (28.5%) | NS (0.6555) |
| Age (y) | 51.4 ± 11.0 | 57.7 ± 8.44 | NS (0.1230) |
| Body mass index (kg/m2) | 29.6 ± 4.30 | 31.2 ± 6.08 | NS (0.5217) |
| Total cholesterol (mmol/L) | |||
| Pretreatment | 6.73 ± 2.32 | 6.88 ± 1.54 | NS (0.8477) |
| Post-treatment | 3.75 ± 1.71 | 3.73 ± 1.34 | NS (0.9740) |
| Triglyceride (mmol/L) | |||
| Pretreatment | 1.62 ± 0.66 | 1.74 ± 0.61 | NS (0.6393) |
| Post-treatment | 1.49 ± 0.70 | 1.91 ± 0.66 | NS (0.1624) |
| HDL-C (mmol/L) | |||
| Pretreatment | 1.22 ± 0.36 | 1.26 ± 0.44 | NS (0.8230) |
| Post-treatment | 1.24 ± 0.36 | 1.33 ± 0.52 | NS (0.6814) |
| LDL-C (mmol/L) | |||
| Pretreatment | 4.77 ± 2.21 | 4.82 ± 1.44 | NS (0.9424) |
| Post-treatment | 1.83 ± 1.52 | 1.67 ± 1.11 | NS (0.7561) |
| Absolute LDL-C reduction (mmol/L) | 2.94 ± 1.22 | 3.15 ± 0.90 | NS (0.6174) |
| Percent change in LDL-C (%) | 63.9 ± 16.0 | 67.7 ± 20.7 | NS (0.6603) |
| Mean wGRS | 1.64 ± 0.18 | 1.95 ± 0.17 | 0.0020 |
| Baseline statin therapy N (%) | |||
| No statin | 3 (9.38) | 3 (42.9) | 0.0261 |
| Low intensity | 1 (3.13) | 0 | NS (0.6356) |
| Moderate intensity | 6 (18.8) | 2 (28.6) | NS (0.5600) |
| High intensity | 22 (68.8) | 2 (28.6) | 0.0478 |
| Ezetimibe therapy N (%) | 22 (68.8) | 4 (57.1) | NS (0.5551) |
Means and standard deviations (SDs) for quantitative variables are shown.
HDL-C, high-density lipoprotein cholesterol; He, heterozygous; LDL-C, low-density lipoprotein cholesterol; N, number of individuals; NS, not significant; wGRS, weighted genetic risk score.